The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...

FAK blocker + chemo + immunotherapy drew immune cells into ovarian tumors in mice. Promising preclinical data; trials next.

Switching from INSTI-based ART to a DOR-based regimen does not lead to clinically meaningful weight loss in adults with HIV and obesity.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating ...

Supplemental New Drug Application for at-home Igalmi aims to provide a self-administered option for agitation in schizophrenia and bipolar disorder.

Immunotherapy and targeted therapy are often the first lines of treatment for advanced kidney cancer, with surgery and ...

Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

Anthropic acquires startup Coefficient Bio for about $400 million per a report by The Information on Friday. To be updated ...

The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROCCTIM-76 Phase 1a trial ongoing, with interim ...

Clinical trial examines a ketogenic nutrition-based approach to addressing the metabolic drivers of PKD As interest ...

Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...